Sanofi (SANP.XC)
| Previous close | 90.97 |
| Open | 90.96 |
| Bid | 90.91 x N/A |
| Ask | 91.36 x N/A |
| Day's range | 90.82 - 91.41 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 1,138 |
| Market cap | 113.643B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 25.16 |
| EPS (TTM) | 3.61 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 3.76 (4.13%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
ZacksPharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
BloombergFrench State Investment Firm Eyes Stake in Sanofi Consumer Unit
(Bloomberg) -- Bpifrance SACA is looking at a potential investment in Sanofi SA’s consumer health unit as it eyes bigger health investments, according to its executive director Jose Gonzalo.Most Read from BloombergBiden’s Fourth of July Shrouded by Pressure to Drop 2024 BidKamala Harris Is Having a Surprise Resurgence as Biden’s Campaign UnravelsSingapore Couples Are Marrying Earlier to Buy Homes, Leading Some to RegretNewsom Shocks California Politics by Scrapping Crime MeasureHouse Democrats C
BloombergBain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
(Bloomberg) -- Private equity firms Bain Capital and Cinven are exploring a potential joint bid for French drugmaker Sanofi SA’s $20 billion consumer health division, people familiar with the matter said.Most Read from BloombergBiden’s Fourth of July Shrouded by Pressure to Drop 2024 BidKamala Harris Is Having a Surprise Resurgence as Biden’s Campaign UnravelsHouse Democrats Consider Demanding Biden Withdraw From RaceNewsom Shocks California Politics by Scrapping Crime MeasureChina Can End Russi
